JP2025519127A5 - - Google Patents

Info

Publication number
JP2025519127A5
JP2025519127A5 JP2024569387A JP2024569387A JP2025519127A5 JP 2025519127 A5 JP2025519127 A5 JP 2025519127A5 JP 2024569387 A JP2024569387 A JP 2024569387A JP 2024569387 A JP2024569387 A JP 2024569387A JP 2025519127 A5 JP2025519127 A5 JP 2025519127A5
Authority
JP
Japan
Prior art keywords
peptide
seq
identity
pain
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024569387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025519127A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/064091 external-priority patent/WO2023227731A1/en
Publication of JP2025519127A publication Critical patent/JP2025519127A/ja
Publication of JP2025519127A5 publication Critical patent/JP2025519127A5/ja
Pending legal-status Critical Current

Links

JP2024569387A 2022-05-25 2023-05-25 疼痛の処置で使用されるペプチド及び方法 Pending JP2025519127A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305773.8 2022-05-25
EP22305773 2022-05-25
PCT/EP2023/064091 WO2023227731A1 (en) 2022-05-25 2023-05-25 Peptides and methods for use in treating pain

Publications (2)

Publication Number Publication Date
JP2025519127A JP2025519127A (ja) 2025-06-24
JP2025519127A5 true JP2025519127A5 (cg-RX-API-DMAC7.html) 2026-05-18

Family

ID=81975215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024569387A Pending JP2025519127A (ja) 2022-05-25 2023-05-25 疼痛の処置で使用されるペプチド及び方法

Country Status (12)

Country Link
US (1) US20250213654A1 (cg-RX-API-DMAC7.html)
EP (1) EP4531886A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025519127A (cg-RX-API-DMAC7.html)
KR (1) KR20250017221A (cg-RX-API-DMAC7.html)
CN (1) CN119730868A (cg-RX-API-DMAC7.html)
AR (1) AR129441A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023275937A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253053A1 (cg-RX-API-DMAC7.html)
IL (1) IL317048A (cg-RX-API-DMAC7.html)
MX (1) MX2024014419A (cg-RX-API-DMAC7.html)
TW (1) TW202409064A (cg-RX-API-DMAC7.html)
WO (1) WO2023227731A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026119985A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating wounds and inflammatory diseases
WO2026119983A1 (en) 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
CN103382220A (zh) * 2012-05-03 2013-11-06 北京大学 具有抗感染、抗肿瘤活性的细胞因子fam19a4及其应用
EP2801369A1 (en) 2013-05-06 2014-11-12 Centre National De La Recherche Scientifique TAFA4 compounds and uses thereof for treating pain
CN108699604A (zh) 2016-03-08 2018-10-23 艾克斯-马赛大学 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途

Similar Documents

Publication Publication Date Title
US20220280593A1 (en) Methods for performing a coronary artery bypass graft procedure
JP2019089773A (ja) ミトコンドリア透過性転移の阻止方法
JP6518197B2 (ja) バース症候群の予防または治療のための方法及び組成物
CN106620645A (zh) 预防或治疗缺血/再灌注损伤之后无复流的方法
US20260008810A1 (en) Analogs that target mitochondrial diseases
AU781678C (en) Compositions and methods for counteracting effects of reactive oxygen species and free radicals
FI3746467T3 (fi) Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö
JP6529606B2 (ja) 自己免疫障害及び炎症障害を治療及び/又は予防するための短い合成ペプチド
KR20160009008A (ko) 심부전과 관련된 위험 및 이와 관련된 인자를 감소시키는 방법
WO2021040526A1 (en) Q-er peptide
JP2022506716A5 (cg-RX-API-DMAC7.html)
JP2025121987A (ja) Glp-1/glp-2デュアルアゴニストの医薬組成物
JP7809117B2 (ja) Glp-1/glp-2デュアルアゴニストの医薬組成物
JP2024547029A5 (cg-RX-API-DMAC7.html)
US20080306075A1 (en) Pharmaceutical Compositions For Transdermal Delivery
US5840697A (en) Peptide inhibitors of calmodulin
WO2011053191A1 (ru) Средство для лечения связанных со стрессовыми условиями заболеваний и расстройств у человека и животных, а также способ лечения и/или профилактики с использованием этого средства
JP2023544910A (ja) コロナウイルス治療法
Kutina et al. Synthesis of new vasotocin analogues: effects on renal water and ion excretion in rats
US10391154B2 (en) Compositions and methods for treating or ameliorating fibrosis, systemic sclerosis and scleroderma
WO2006101909A2 (en) Combination therapy for treating or preventing diseases
KR102689456B1 (ko) 알파-1 안티트립신을 포함하는 면역억제제에 의한 신장손상 예방 또는 치료용 조성물
CN119708140A (zh) 肽化合物及其治疗疾病的方法
WO2003020301A1 (en) Chromogranin a and fragments thereof for the treatment of diseases involving increased vascular permeability
WO2025123051A1 (en) Non-naturally occurring melanocortin analogs and uses thereof for modulating weight gain